SCHEMBL21709427

SCHEMBL21709427

CC1(C)c2ccccc2-c2c(N(c3ccc(-c4ccccc4)cc3)c3ccc4oc5ccc(-c6nc(-c7ccccc7)c7ccccc7n6)cc5c4c3)cccc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ATM Q13315 1/20 0.36
PDK1 Q15118 2/20 0.33
WHR1 P49842 1/20 0.32
KDM1A O60341 1/20 0.32
CYP1A2 P05177 2/20 0.31
CYP3A4 P08684 2/20 0.31
CYP2D6 P10635 2/20 0.31
CYP2C9 P11712 2/20 0.31
CYP2C19 P33261 2/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
GLA P06280 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
RECQL P46063 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21709325 0.96 MEN1 (0.34) MEN1KMT2AATMPDK1WHR1
SCHEMBL21709333 0.96 MEN1 (0.34) MEN1KMT2AATMPDK1WHR1
SCHEMBL21709383 0.96 MEN1 (0.38) MEN1KMT2AATMPDK1WHR1
SCHEMBL21709311 0.95 MEN1 (0.35) MEN1KMT2AATMPDK1WHR1
SCHEMBL21709498 0.93 MEN1 (0.34) MEN1KMT2AATMPDK1WHR1
SCHEMBL21709416 0.93 MEN1 (0.33) MEN1KMT2AATMPDK1NUDT1
SCHEMBL21709472 0.93 MEN1 (0.32) MEN1KMT2AATMNUDT1
SCHEMBL21778721 0.90
SCHEMBL21709425 0.89 MEN1 (0.45) MEN1KMT2AATMPDK1WHR1
SCHEMBL21709414 0.89 MEN1 (0.45) MEN1KMT2AATMPDK1WHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES MERCK PATENT GMBH (DE) 2020-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES DDT, NAT1, INMT MEN1 2014/4885KMT2A 242/4885ATM 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.